Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

AcelRx Pharmaceuticals logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

Key Stats

Today's Range
N/A
50-Day Range
$0.49
$0.86
52-Week Range
N/A
Volume
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

AcelRx Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
38th Percentile Overall Score

ACRX MarketRank™: 

AcelRx Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 774th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AcelRx Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about AcelRx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for ACRX.
  • Dividend Yield

    AcelRx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    AcelRx Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ACRX.
    • Insider Buying vs. Insider Selling

      In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 3.00% of the stock of AcelRx Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      Only 19.79% of the stock of AcelRx Pharmaceuticals is held by institutions.

    • Read more about AcelRx Pharmaceuticals' insider trading history.
    Receive ACRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    ACRX Stock News Headlines

    The real reason Elon is fully endorsing Trump
    Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
    See More Headlines

    ACRX Stock Analysis - Frequently Asked Questions

    AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings data on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, meeting the consensus estimate of ($1.40). The specialty pharmaceutical company earned $1.86 million during the quarter, compared to analysts' expectations of $1.20 million.

    AcelRx Pharmaceuticals shares reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Sorrento Therapeutics (SRNE).

    Company Calendar

    Last Earnings
    11/15/2021
    Today
    10/31/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:ACRX
    Employees
    19
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $5.00
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $5.00
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Net Income
    $47.76 million
    Pretax Margin
    -3,711.25%

    Debt

    Sales & Book Value

    Annual Sales
    $1.77 million
    Book Value
    $2.65 per share

    Miscellaneous

    Free Float
    16,443,000
    Market Cap
    $14.58 million
    Optionable
    Optionable
    Beta
    0.52

    Social Links

    7 Energy Stocks to Buy and Hold Forever Cover

    Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

    Get This Free Report

    This page (NASDAQ:ACRX) was last updated on 10/31/2024 by MarketBeat.com Staff
    From Our Partners